Authenticating Translational ADME Reagents for Gold-Standard Science Using Quantitative Proteomic and Transcriptomic Profiling of Primary Cells: The Case Example of HepatoXcell™
February 19, 2026, at 12:00 PM ETAccurately modeling human hepatic drug metabolism and transporter function remains a central challenge in ADME and non-animal model (NAM) workflows, particularly as laboratories seek experimental systems that balance physiological relevance with lot-to-lot consistency and scalability. This webinar will open with an overview from ATCC describing the phenotypic characteristics and performance of HepatoXcell primary human hepatocytes across ADME-relevant assays. Next, ATCC experts will present transcriptomic profiling data to assess interdonor and lot-to-lot variability across HepatoXcell preparations. Precision Quantomics will follow with a demonstration of how quantitative proteomic characterization of drug-metabolizing enzymes and membrane transporters via targeted LC-MS–based methods can define the functional protein landscape of microphysiological system models with high specificity and dynamic range. Finally, we will illustrate how these protein-abundance profiles, contextualized against primary human hepatocytes and reference datasets, can be used to evaluate concordance, divergence, and translational implications for in vitro to in vivo (IVIVE) and physiologically based pharmacokinetic (PBPK) modeling. Collectively, these complementary transcriptomic and proteomic analyses establish a rigorous framework for assessing the suitability of primary hepatocyte models for predictive pharmacokinetics, mechanistic toxicology, and broader NAM-aligned workflows.
Key takeaways:
- HepatoXcell™ primary human hepatocytes provide physiologically relevant and consistent performance across ADME assays, helping scientists build more reliable NAM workflows.
- Transcriptomic profiling across donors gives researchers greater confidence in model predictability and reducing experimental uncertainty.
- Targeted LC‑MS proteomics precisely quantify drug‑metabolizing enzymes and transporters, enabling deep insight into the functional protein landscape of hepatic models.
- Integrating transcriptomic and proteomic data enhances model accuracy, supporting stronger translational decisions in predictive pharmacokinetics and mechanistic toxicology.
Presenters:
Ajeet Singh, PhD
Senior Scientist, ATCC
Dr. Ajeet Singh is Senior Scientist at ATCC where he is focused on providing reference-grade whole transcriptome data that is authenticated, standard, and traceable to physical source materials available in ATCC’s biorepository. Prior to joining ATCC, Dr. Singh received his PhD in Agricultural Plant Pathology where he performed research focused on epidemiology and integrated management of plants pests and diseases. He then performed postdoctoral research at the National Institute of Environmental Health Sciences and subsequently worked as a Senior Staff Scientist at the National Cancer Institute. Dr. Singh has extensive experience in biomedical research with his research career expanding an array of interrelated disciplines exploring epigenetics, chromatin and gene expression in reproductive developmental toxicology, stem cell biology, and cancer.
Bhagwat Prasad, PhD
Chief Scientific Officer, Precision Quantomics, Inc;
Division Director of Translational and Clinical Pharmacology, Cincinnati Children’s Hospital Medical Center (CCHMC)
Dr. Bhagwat Prasad is Professor of Pediatrics and Division Director of Translational and Clinical Pharmacology at Cincinnati Children’s Hospital Medical Center (CCHMC). He also serves as Chief Scientific Officer of Precision Quantomics, Inc., an independent biotechnology company. His research, supported by federal agencies and industry partners, focuses on interindividual variability in drug disposition and the IVIVE of drug transport, metabolism, and response using quantitative proteomics and metabolomics. He also directs the multi‑sponsor PRINCE consortium, advancing proteomics‑informed drug metabolism science. Prior to joining CCHMC, Dr. Prasad was a Tenured Professor at Washington State University and previously served on the faculty at the University of Washington. He has authored over 150 peer‑reviewed publications and delivered more than 125 invited lectures across academia, industry, and the U.S. FDA. Dr. Prasad is an elected member of the Washington State Academy of Sciences and recipient of notable honors including the ISSX New Investigator Award (2018), the ASPET Early Career Award (2018), and WSU Chancellor’s Excellence Awards in Service (2022) and Research (2024). He currently chairs the ASPET Drug Metabolism and Disposition Division and the ISSX Transporter Focus Group. He also serves on the editorial boards of Drug Metabolism & Disposition, Clinical Pharmacology & Therapeutics, Trends in Analytical Chemistry, Frontiers in Pharmacology, and Pharmaceutics. He earned his MS and PhD in Pharmaceutical Sciences from NIPER, India, completed postdoctoral training at the University of Washington, and served as a Visiting Faculty Fellow at the U.S. FDA in 2024.
